Society for Translational Oncology navigateright Episode
Laura M. Spring, MD
Massachusetts General Hospital
Boston, MA, USA
We are exploring predictors of response and resistance to neoadjuvant therapies for localized breast cancer, including the use of blood-based biomarkers, such as circulating tumor cells and circulating tumor DNA. If validated in the neoadjuvant setting, this approach could provide an important opportunity to individualize therapy, thereby minimizing unnecessary systemic toxicity associated with ineffective therapies, and could ultimately improve clinical outcomes.
These lectures are designed to meet the educational needs of physicians and scientists in academic and practice settings who wish to advance their knowledge of the research into new treatments and improve their competence in the care of patients with cancer.